<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34711961</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1534</StartPage><EndPage>1541</EndPage><MedlinePgn>1534-1541</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-021-00936-z</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a relentless neurodegenerative disease of the human motor neuron system, where variability in progression rate limits clinical trial efficacy. Therefore, better prognostication will facilitate therapeutic progress. In this study, we investigated the potential of plasma cell-free microRNAs (miRNAs) as ALS prognostication biomarkers in 252 patients with detailed clinical phenotyping. First, we identified, in a longitudinal cohort, miRNAs whose plasma levels remain stable over the course of disease. Next, we showed that high levels of miR-181, a miRNA enriched in neurons, predicts a&#x2009;greater than two-fold risk of death in independent discovery and replication cohorts (126 and 122 patients, respectively). miR-181 performance is similar to neurofilament light chain (NfL), and when combined together, miR-181 + NfL establish a novel RNA-protein biomarker pair with superior prognostication capacity. Therefore, plasma miR-181 alone and a novel miRNA-protein biomarker approach, based on miR-181 + NfL, boost precision of patient stratification. miR-181-based ALS biomarkers encourage additional validation and might enhance the power of clinical trials.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Magen</LastName><ForeName>Iddo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yacovzada</LastName><ForeName>Nancy Sarah</ForeName><Initials>NS</Initials><Identifier Source="ORCID">0000-0002-5152-8775</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanowski</LastName><ForeName>Eran</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coenen-Stass</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Translational Medicine, Merck Healthcare KGaA, Darmstadt, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, University College London, Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grosskreutz</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Precision Neurology, Department of Neurology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Healthy Aging, Department of Neurology, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ching-Hua</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, University College London, Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology, School of Medicine, China Medical University and Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ALS Biomarkers Study, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greensmith</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, University College London, Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ALS Biomarkers Study, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8020-7567</Identifier><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, University College London, Queen Square Institute of Neurology, London, UK. a.malaspina@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, Queen Square Institute of Neurology, London, UK. a.malaspina@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. a.malaspina@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ALS Biomarkers Study, University College London, London, UK. a.malaspina@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratta</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-8762-8188</Identifier><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, University College London, Queen Square Institute of Neurology, London, UK. p.fratta@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, Queen Square Institute of Neurology, London, UK. p.fratta@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ALS Biomarkers Study, University College London, London, UK. p.fratta@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornstein</LastName><ForeName>Eran</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-5534-1924</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel. eran.hornstein@weizmann.ac.il.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel. eran.hornstein@weizmann.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FRATTA/JAN15/946-795</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S006508/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>GREENSMITH/APR15/839-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M008606/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MALASPINA/APR13/817-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C540193">MIrn181 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34711961</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00936-z</ArticleId><ArticleId IdType="pii">10.1038/s41593-021-00936-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Munsat, T. L., Andres, P. L., Finison, L., Conlon, T. &amp; Thibodeau, L. The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology 38, 409&#x2013;413 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3347345</ArticleId><ArticleId IdType="doi">10.1212/WNL.38.3.409</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits, J. M. &amp; La Spada, A. R. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 73, 805&#x2013;811 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19738176</ArticleId><ArticleId IdType="pmc">2739608</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181b6bbbd</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar, M. et al. ALS biomarkers for therapy development: state of the field and future directions. Muscle Nerve 53, 169&#x2013;182 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26574709</ArticleId><ArticleId IdType="doi">10.1002/mus.24979</ArticleId></ArticleIdList></Reference><Reference><Citation>Chipika, R. H., Finegan, E., Li Hi Shing, S., Hardiman, O. &amp; Bede, P. Tracking a fast-moving disease: longitudinal markers, monitoring, and clinical trial endpoints in ALS. Front. Neurol. 10, 229 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30941088</ArticleId><ArticleId IdType="pmc">6433752</ArticleId><ArticleId IdType="doi">10.3389/fneur.2019.00229</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber, N. S. et al. Biomarkers in motor neuron disease: a state of the art review. Front. Neurol. 10, 291 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31001186</ArticleId><ArticleId IdType="pmc">6456669</ArticleId><ArticleId IdType="doi">10.3389/fneur.2019.00291</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi, D. et al. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J. Neurol. 265, 510&#x2013;521 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29322259</ArticleId><ArticleId IdType="doi">10.1007/s00415-017-8730-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves, M. et al. Phosphoneurofilament heavy chain and vascular endothelial growth factor as cerebrospinal fluid biomarkers for ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 18, 134&#x2013;136 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27538346</ArticleId><ArticleId IdType="doi">10.1080/21678421.2016.1212894</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, C. H. et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J. Neurol. Neurosurg. Psychiatry 86, 565&#x2013;573 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25009280</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2014-307672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Garza, M. T., Martinez, H. R., Cruz-Vega, D. E., Hernandez-Torre, M. &amp; Moreno-Cuevas, J. E. Adipsin, MIP-1b, and IL-8 as CSF biomarker panels for ALS diagnosis. Dis. Markers 2018, 3023826 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30405855</ArticleId><ArticleId IdType="pmc">6199888</ArticleId><ArticleId IdType="doi">10.1155/2018/3023826</ArticleId></ArticleIdList></Reference><Reference><Citation>Prado, L. G. R. et al. Longitudinal assessment of clinical and inflammatory markers in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 394, 69&#x2013;74 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30219498</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2018.08.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, C. H. et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 3, e244 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27308305</ArticleId><ArticleId IdType="pmc">4897985</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000244</ArticleId></ArticleIdList></Reference><Reference><Citation>Haramati, S. et al. miRNA malfunction causes spinal motor neuron disease. Proc. Natl Acad. Sci. USA 107, 13111&#x2013;13116 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20616011</ArticleId><ArticleId IdType="pmc">2919953</ArticleId><ArticleId IdType="doi">10.1073/pnas.1006151107</ArticleId></ArticleIdList></Reference><Reference><Citation>Emde, A. et al. Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. EMBO J. 34, 2633&#x2013;2651 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26330466</ArticleId><ArticleId IdType="pmc">4641530</ArticleId><ArticleId IdType="doi">10.15252/embj.201490493</ArticleId></ArticleIdList></Reference><Reference><Citation>Eitan, C. &amp; Hornstein, E. Vulnerability of microRNA biogenesis in FTD&#x2013;ALS. Brain Res. 1647, 105&#x2013;111 (2016).</Citation></Reference><Reference><Citation>Takahashi, I. et al. Identification of plasma microRNAs as a biomarker of sporadic amyotrophic lateral sclerosis. Mol. Brain 8, 67 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26497046</ArticleId><ArticleId IdType="pmc">4619470</ArticleId><ArticleId IdType="doi">10.1186/s13041-015-0161-7</ArticleId></ArticleIdList></Reference><Reference><Citation>de Andrade, H. M. et al. MicroRNAs-424 and 206 are potential prognostic markers in spinal onset amyotrophic lateral sclerosis. J. Neurol. Sci. 368, 19&#x2013;24 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27538595</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2016.06.046</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheinerman, K. S. et al. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimers Res. Ther. 9, 89 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29121998</ArticleId><ArticleId IdType="pmc">5679501</ArticleId><ArticleId IdType="doi">10.1186/s13195-017-0316-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny, G. et al. A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients. Cell Death Discov. 7, 4 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33431881</ArticleId><ArticleId IdType="pmc">7801652</ArticleId><ArticleId IdType="doi">10.1038/s41420-020-00397-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Benigni, M. et al. Identification of miRNAs as potential biomarkers in cerebrospinal fluid from amyotrophic lateral sclerosis patients. Neuromolecular Med. 18, 551&#x2013;560 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27119371</ArticleId><ArticleId IdType="doi">10.1007/s12017-016-8396-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Coenen-Stass, A. M. L. et al. Evaluation of methodologies for microRNA biomarker detection by next generation sequencing. RNA Biol. 15, 1133&#x2013;1145 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30223713</ArticleId><ArticleId IdType="pmc">6161688</ArticleId></ArticleIdList></Reference><Reference><Citation>Og&#x142;uszka, M., Orzechowska, M., J&#x119;droszka, D., Witas, P. &amp; Bednarek, A. K. Evaluate Cutpoints: adaptable continuous data distribution system for determining survival in Kaplan&#x2013;Meier estimator. Comput. Methods Prog. Biomed. 177, 133&#x2013;139 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2019.05.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin, P. C. &amp; Tu, J. V. Bootstrap methods for developing predictive models. Am. Statistician 58, 131&#x2013;137 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1198/0003130043277</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng, H. J. et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 17, 423&#x2013;433 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbach, R. et al. Disease aggressiveness signatures of amyotrophic lateral sclerosis in white matter tracts revealed by the D50 disease progression model. Hum. Brain Mapp. 42, 737&#x2013;752 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33103324</ArticleId><ArticleId IdType="doi">10.1002/hbm.25258</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichenstein, I. et al. Human genetics and neuropathology suggest a link between miR-218 and amyotrophic lateral sclerosis pathophysiology. Sci. Transl. Med. 11, eaav5264 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31852800</ArticleId><ArticleId IdType="pmc">7057809</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aav5264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig, N. et al. Distribution of miRNA expression across human tissues. Nucleic Acids Res. 44, 3865&#x2013;3877 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921406</ArticleId><ArticleId IdType="pmc">4856985</ArticleId><ArticleId IdType="doi">10.1093/nar/gkw116</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577&#x2013;589 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, C. H. et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84, 2247&#x2013;2257 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25934855</ArticleId><ArticleId IdType="pmc">4456658</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen, K. &amp; Van Damme, P. Diagnostic and prognostic performance of neurofilaments in ALS. Front. Neurol. 9, 1167 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30713520</ArticleId><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar, M. et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95, e59&#x2013;e69 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32385188</ArticleId><ArticleId IdType="pmc">7371380</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000009559</ArticleId></ArticleIdList></Reference><Reference><Citation>Corradi, E. et al. Axonal precursor miRNAs hitchhike on endosomes and locally regulate the development of neural circuits. EMBO J. 39, e102513 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32073171</ArticleId><ArticleId IdType="pmc">7073465</ArticleId><ArticleId IdType="doi">10.15252/embj.2019102513</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, C.-Z., Li, L., Lodish, H. F. &amp; Bartel, D. P. MicroRNAs modulate hematopoietic lineage differentiation. Science 303, 83 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14657504</ArticleId><ArticleId IdType="doi">10.1126/science.1091903</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar, M., Wuu, J., Andersen, P. M., Lombardi, V. &amp; Malaspina, A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 84, 130&#x2013;139 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId><ArticleId IdType="doi">10.1002/ana.25276</ArticleId></ArticleIdList></Reference><Reference><Citation>Puentes, F. et al. Immune reactivity to neurofilaments and dipeptide repeats in ALS progression. Preprint at https://www.biorxiv.org/content/10.1101/2020.02.25.965236v1 (2020).</Citation></Reference><Reference><Citation>Puentes, F. et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 85, 274&#x2013;278 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24078718</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2013-305494</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks, B. R., Miller, R. G., Swash, M., Munsat, T. L. &amp; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 1, 293&#x2013;299 (2000).</Citation></Reference><Reference><Citation>Cedarbaum, J. M. et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J. Neurol. Sci. 169, 13&#x2013;21 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen, K. et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 88, 2302&#x2013;2309 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28500227</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell, T. et al. Reaction to endoplasmic reticulum stress via ATF6 in amyotrophic lateral sclerosis deteriorates with aging. Front. Aging Neurosci. 11, 5 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30740050</ArticleId><ArticleId IdType="pmc">6355670</ArticleId><ArticleId IdType="doi">10.3389/fnagi.2019.00005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohen, R. et al. UTAP: user-friendly transcriptome analysis pipeline. BMC Bioinformatics 24, 154 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-019-2728-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozomara, A. &amp; Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42, D68&#x2013;D73 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24275495</ArticleId><ArticleId IdType="doi">10.1093/nar/gkt1181</ArticleId></ArticleIdList></Reference><Reference><Citation>Love, M. I., Huber, W. &amp; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25516281</ArticleId><ArticleId IdType="pmc">4302049</ArticleId><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi, V. et al. Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology 92, e1205&#x2013;e1211 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30787165</ArticleId><ArticleId IdType="pmc">6511101</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng, T. et al. A BaSiC tool for background and shading correction of optical microscopy images. Nat. Commun. 8, 14836 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28594001</ArticleId><ArticleId IdType="pmc">5472168</ArticleId><ArticleId IdType="doi">10.1038/ncomms14836</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders, S. &amp; Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20979621</ArticleId><ArticleId IdType="pmc">3218662</ArticleId><ArticleId IdType="doi">10.1186/gb-2010-11-10-r106</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. &amp; Golani, I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 125, 279&#x2013;284 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11682119</ArticleId><ArticleId IdType="doi">10.1016/S0166-4328(01)00297-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell, F. E. Jr., Lee, K. L., Califf, R. M., Pryor, D. B. &amp; Rosati, R. A. Regression modelling strategies for improved prognostic prediction. Stat. Med. 3, 143&#x2013;152 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6463451</ArticleId><ArticleId IdType="doi">10.1002/sim.4780030207</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubbs, F. E. Procedures for detecting outlying observations in samples. Technometrics 11, 1&#x2013;21 (1969).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00401706.1969.10490657</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2015).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>